Proxy Results (Form 8-K)

Amylyx Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders on June 5, 2025 (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2025. The final voting results are set forth below.

Proposal 1 - Election of Class I Directors

The stockholders of the Company elected Karen Firestone, Justin Klee, and Bernhardt Zeiher, M.D. as Class I directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2028 or until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class I directors were as follows:

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders' vote with respect to such ratification were as follows:

Proposal 3 - Non-Binding,Advisory Vote on the Compensation of the Company's Named Executive Officers

The stockholders of the Company approved, on a non-binding,advisory basis, the compensation of the Company's named executive officers. The results of the stockholders' vote with respect to such approval were as follows:

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.